<DOC>
	<DOCNO>NCT01450514</DOCNO>
	<brief_summary>This Phase I/IIa Proof-of-Concept ( PoC ) trial design assess effect add single repeat low dose ( 15mg/d ) pipamperone ( PIP ) 6 week stable treatment effective dose risperidone ( RIS ) paliperidone ( PAL ) functional MRI test clinical outcome chronic schizophrenic patient residual , so-called 'positive ' symptom , well cognition , motivation , subjective well-being patient , negative symptom , general psychopathological symptom safety/tolerability .</brief_summary>
	<brief_title>POC Study Pipamperone Added Stable Treatment With RIS PAL Chronic Schizophrenia</brief_title>
	<detailed_description>This exploratory study 7 week intend perform 40 60 patient 10 center Belgium . In subset patient , 6-week treatment phase precede single-dose cross-over phase 1 week wash-out . While objective study , due exploratory design , assess effect study medication MRI clinical outcome , study medication expect improve residual ( remain ) positive symptom ( ) patient . In addition , genetic pharmacokinetic testing may perform learn disorder treatment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Pipamperone</mesh_term>
	<criteria>Patient inform give ample time opportunity think her/his participation give her/his write informed consent . Patient understand investigational nature trial willing able comply trial requirement . Patient male female , age 1865 year . Patients Schizophrenia Schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders ( DSM ) IVR criterion . Diagnosis confirm Mini International Neuropsychiatric Interview ( MINI ) Patient treat least 12 week stable dosage either risperidone depot 12.550mg IM every 2 week , paliperidone depot 25100mg IM every 4 week , risperidone oral administration 26 mg/d , paliperidone oral administration 412 mg/d Patient CGIS score 3 ( mildly ill ) baseline . Patient score 4 least 1 item positive PANSS subscale ( residual symptom ) . Acute exacerbation schizophrenic schizoaffective disorder past 12 week . Documented debility IQ 85 . Comorbid axis 1 condition ( include anxiety disorder , eat disorder , impulse control disorder ) require drug treatment previous 12 week . Patient take , past 6 week prior randomization , newly initiate psychoactive drug . Patient withdraw psychoactive drug treatment past week within period shorter 5x elimination halflife psychoactive drug . Withdrawal prior antipsychotic treatment occur within 6 week prior baseline . Concomitant treatment additional antipsychotic drug therapeutic dosage , diuretic , QT prolongation drug , dopamine agonist . Formal cognitive psychotherapy initiate study treatment within 6 week prior randomization . Patient medical psychiatric condition , opinion investigator , jeopardize would compromise patient 's ability participate trial would interfere trial assessment . Patient DSMIV alcohol substance dependence diagnosis ( within last 6 month ) , alcohol substance abuse diagnosis ( within last month ) positive standard screen alcohol drug ( include benzodiazepine opioids ) . 'Any concomitant psychoactive treatment ( include psychotherapy ) ' 'Patient receive , 6 week prior randomization newly prescribe psychoactive drug ' . Patient pregnant , nursing , woman childbearing potential surgically sterile , 2 year postmenopausal , consistently use 2 combined effective method contraception ( include least 1 barrier method ) , unless sexually abstinent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>